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Abstract  
 
Introduction: The efficacy of rituximab (RTX) in Systemic Lupus Erythematosus (SLE) is 
debated. We describe the outcomes of a European SLE cohort treated with RTX, with 
emphasis on its role as a maintenance agent. 
 
Methods: All patients with SLE receiving RTX as induction across four centres were included, 
follow-up post RTX was collected including the subgroup treated with RTX as maintenance 
treatment (RMT). Disease flares during the follow-up were defined as an increase in disease 
activity and immunosuppressive drugs. 
 
Results: Of 147 patients, at 6 months 27% experienced treatment failure (TF); in a 
multivariate analysis, a low number of previous immunosuppressive therapies (p=0.034) and 
low C4 levels (p=0.008) reduced the risk of TF. Eighty patients received RMT over a median 
of 24.5 months during which 85 relapses, mainly musculoskeletal, were recorded (1.06 per 
patient); at the last RTX course, 84% of the patients were in remission. 28/80 (35%) patients 
never flared during the RMT with low damage accrual; active articular disease at the time of 
the first RTX course was associated with risk of flare during RMT (p=0.010). After RMT, 
relapse free survival was similar to patients receiving a single-RTX course (p=0.72). 
 
Conclusions:  
RMT is a potential treatment option in difficult to treat patients. Relapses occur during RMT 
and are more likely in those with active articular disease at the time of the first RTX. Relapse 
risk after RMT remains high and apparently comparable to the one seen after a single-RTX 
course. 
 
INTRODUCTION 
Systemic Lupus Erythematosus (SLE) is an autoimmune disease characterised by clinical 
variability and complex pathogenesis(1, 2). B-cell depleting strategies have received 
continued attention in SLE(1) and, although rituximab (RTX) has proven effective in other 
autoimmune diseases characterised by hyperactivity of the B-cell compartment(3), 
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randomised controlled trials (RCTs) exploring RTX in SLE(4, 5) have failed to meet their 
primary end-points.  
 
Sustained remission is the goal for disease management although infrequently achieved(6); 
improving the management of the maintenance phase of SLE is therefore an unmet need(7). 
Newer therapeutic options are needed and RTX is frequently employed in relapsing and 
refractory cases(8), its use is supported by retrospective and prospective non-randomised 
studies(1). 
 
The discrepancy between the RCTs results and those observed in real-life settings suggests 
that solid predictors of response to RTX must be identified in order to better tailor the 
treatment strategies. Clinical predictors of response to RTX in SLE have been investigated, 
with heterogeneous results across different cohorts(9). Having severe disease, lack of 
haematological involvement or previous treatment with high dose steroids were associated 
with a good response in 116 patients(10); younger age and achievement of B-cell depletion 
six weeks after treatment with RTX were other favourable characteristics in a different 
population of 117 patients(11). Among biomarkers, the proportion of plasmablasts 6 
months after RTX(11) and a single nucleotide polymorphism in the IL2/IL21 area have been 
associated with response(12); the former replicated in two different cohorts while the 
latter, although with a strong biological rationale(13), so far replicated only in a cohort of 
patients with microscopic polyangiitis(14).  
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Importantly, in RTX treated patients time to relapse is highly variable(15, 16); relapses are 
associated to risk of damage accrual and therefore attention should be focused on flare 
prevention aiming at the right balance between immunosuppressive drug dosing, risk of 
toxicity and disease activity. RTX has a proven role as a maintenance agent in other 
autoimmune diseases(3) while in SLE, there is little published experience of repeat dose 
RTX(17-21). Of note the cohorts were small, the number of cycles low and the indications 
for repeating the treatment heterogeneous while no study has so far explored its use as 
maintenance treatment with the aim of relapse prevention. 
 
In this study, we explore the efficacy and safety of RTX in a cohort of 147 patients with SLE 
with an emphasis on the subgroup of 80 patients re-treated with the drug as a maintenance 
agent in order to prevent relapses; prognostic factors associated with the response to RTX 
were also investigated. 
 
PATIENTS AND METHODS. 
Data on all patients with a diagnosis of SLE according to ACR or SLICC criteria that 
received at least one RTX administration from 2004 to 2016 were collected 
retrospectively at four centres: Addenbrooke’s Hospital (Cambridge UK), ASST Santi 
Paolo e Carlo-San Carlo Borromeo Hospital (Milan IT), Policlinico Hospital (Milan IT) 
and Careggi Hospital (Florence IT). Ethical approval was obtained only at the Italian 
centres; it was not required in the UK centre due to the retrospective nature of the 
work.  
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Treatment protocol 
The patients were either treated with a “Single-RTX course” or with  “RTX maintenance 
treatment” (RMT). “Single-RTX course” was any RTX dosing performed within a single 
month, such as 1 g or 375 mg/m2 given two weeks apart or for four consecutive weeks 
respectively. Patients receiving at least three “Single-RTX courses” with the aim of 
relapse prevention and with an interval of 4 to 8 months between consecutive 
treatments were classified as receiving RMT. Patients receiving RTX courses that did 
not meet this definition were censored at time of re-treatment. Treatment associated to 
RTX administration and data collected during the follow-up are reported in the 
supplementary methods. This a retrospective study, therefore no clear indications for 
treatment selection as well as RTX schedule within the RMT group was provided and it 
was result of the single physician experience and choice. 
 
Assessments 
Disease activity was assessed using the European Consensus Lupus Activity 
Measurement (ECLAM) score(22) since validated for retrospective studies(23), and the 
physician assessment (PA); the type and dose of immunosuppressive therapies was also 
recorded. PA was zero if no signs of active SLE were identified, 1 if the disease activity 
was mild and 2 if this was severe.  
 
Response to the first RTX course assessed after six months was defined as complete 
response (CR), for PA of 0 or 1, a reduction of ECLAM of at least 50% and decrease of 
the immune-modulating therapy (considering one between corticosteroids or 
immunesuppressors but no anti-malarials) by at least 25% from baseline; partial 
response (PR) for ECLAM reduction of 25-50%, PA >0 and reduction of the immune-
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modulating therapy dose of 0-25%.  Any other case was defined as treatment failure 
(TF). 
 
Disease flares during RMT or after the first-last RTX course were defined as an increase 
in at least two of three parameters among PA, ECLAM, immunosuppressive-
corticosteroids number/dose.  
 
Patients were stratified in four groups according to disease severity: Mild, Moderate, 
Severe and Drug Sparing. The first three groups were defined according to the British 
Society of Rheumatology guidelines(8); the group “Drug Sparing” included patients with 
Mild or Moderate disease to whom RTX was administered with the aim of sparing an 
on-going immunosuppressive agent or avoiding an alternative immune suppressors 
contraindicated for the patient. 
 
Late onset neutropenia (LON) definition and damage assessment methods are reported 
in the supplementary methods. 
 
Statistical Analysis  
Statistical analysis was performed using R (https://www.r-project.org), GraphPad 
Prism 7 (GraphPad Software, La Jolla, CA, USA) and SAS statistical software (version 9.4; 
SAS Institute, Cary, NC, USA). Results are expressed as count and percentage for 
categorical variables and median (interquartile range, IQR) or mean (95% confidence 
interval, 95% CI) for continuous variables.  
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Methods for comparison of changes in variables and proportions of patients as well as 
for Univariate and multiple logistic regression are reported in the supplementary 
methods. 
 
Time to relapse was assessed by the Kaplan-Meier survival analysis, and if comparisons 
between populations were required, the log-rank test was used. Two sided p-values 
<0.05, were considered statistically significant. 
 
RESULTS 
Outcome after the first RTX 
The clinical characteristics at the time of the first RTX administration for the whole 
cohort are reported in Table 1. The mean (95%CI) number of previous 
immunosuppressive drug employed in the four groups of disease severity Mild, 
Moderate, Severe and Drug Sparing was 2.92 (2.38-3.46), 2.74 (1.84-3.64), 2.38 (2.04-
2.72) and 2.42 (1.97-2.87) respectively. 
 
Six months after the first RTX administration, 67 (45%) patients were in CR and 41 in 
PR (28%), while 39 (27%) experienced TF.  The ECLAM score declined from 4 at 
baseline (mean, 95%CI 3.65-4.34) to 1.9 at 6 months (1.66-2.14) (p<0.0001); the 
prednisolone dose declined from a mean of 15.4 (95%CI 13.1-17.7) to 8.45 (7.29-9.61) 
(p<0.0001). Within the four groups of disease severity Mild, Moderate, Severe and Drug 
Sparing the proportion of TF at 6 months was 65%, 50%, 25% and 6% respectively. 
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At the multivariate analysis adjusted for confounding factors (other 
immunosuppressive drugs administered and prednisolone dose), the characteristics 
associated with the risk of experiencing TF were higher C4 levels (OR 1.76 (1.15-2.7), 
p=0.008) and the number of previous immunosuppressive agents (OR 7.77 (1.65-36.6), 
p=0.034) (Table S1). 
 
RTX Maintenance Treatment (RMT) 
80/147 (54%) patients were treated with RMT; their characteristics are summarised in 
Table 1. Their median duration of maintenance treatment was 24 months (IQR 16-34; 
range 11-99 months), the median cumulative RTX dose was 6 gm (IQR 4.87-9 gm) and 
the median overall follow-up was 38 months (IQR 22-54). At the time of the first RTX 
administration, 69/80 patients (86%) were receiving a mean oral prednisolone dose of 
11 mg/day (95%CI 9-13) and 46 (57%) were receiving an immunosuppressive drug 
(not including hydroxychloroquine): 28 mycophenolate mofetil, 6 methotrexate, 4 
azathioprine, 4 cyclophosphamide, 4 calcineurin inhibitors, 3 intravenous 
immunoglobulin and 4 other treatments.  The mean ECLAM score at the first RTX was 
3.5 (95%CI 3.06-3.93) and the mean (95%CI) number of previous immunosuppressive 
drug employed in the four groups of severity of disease Mild, Moderate, Severe and 
Drug Sparing were respectively 3.05 (2.28-3.82), 3.67 (2.7-4.64), 2.42 (2.06-2.78) and 
2.14 (1.64-2.64). The different protocols employed for RTX administration within the 
RMT group are reported in the paragraph RTX schedule of administration within RMT 
of the supplementary material. 
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 After six months ECLAM declined to a mean of 1.86 (95%CI 1.52-2.19) (p<0.0001) with 
a trend towards further reduction/stabilisation during maintenance treatment (figure 
1); at the six month assessment 30/80 patients (38%) were in CR and this proportion 
increased to 40–51 and 48% respectively at the 12, 18 and 24 month assessment. The 
proportion of patients not taking corticosteroids increased from 14% to 41% while the 
mean dose of prednisolone dropped from 11 mg/day (95%CI 8.9-13) at RTX initiation 
to 3.8 (95%CI 1.1-6.4) by the 6th administration; a trend towards a reduction of the 
proportion of patients receiving other immunosuppressive drugs was also observed 
(figure 1). 
 
52/80 (65%) patients experienced 85 relapses (1.06 relapses per patient, 53 per 100-
patient year) after a median of 11.5 months (IQR 8-18.25); relapses were more frequent 
between 6-12 months after the first RTX administration (Table S2) and more 
frequently involved joints (66%) and skin (40%) (Table S3). At the time of flare, the 
mean ECLAM score was 2.72 (95%CI 2.42-3.03) and its mean increase compared to the 
previous assessment was 1.42 (95%CI 1.11-1.74). Relapses were managed with an 
increase in prednisolone dose in 29/85 cases (34%) [mean increase 11.1 mg (95%CI 
6.9-15.4)], with a new immunosuppressive drug in 22/85 (26%), with an increase in the 
dose of an on-going immunosuppressive drug in 12/85 (14%), 7/85 (8%) patients were 
managed by bringing forward the pre-planned RTX administration while in 15/85 
(18%) the flare was managed by waiting for the pre-planned RTX infusion.  
 
At the time of the last RTX administration, 67/80 (84%) of the patients were in 
remission, the mean ECLAM score was 1.5 (IQR 1.13-1.86) and the mean prednisolone 
dose was 6.35 mg/day (95%CI 4.8-7.9). 
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Outcome after the last RTX infusion 
Of the 67 patients that received a single-RTX course, 54 (80%) experienced a CR or PR 
at the sixth month assessment and were therefore followed for post therapy flare; the 
median follow-up after the sixth month assessment was 7.3 months (IQR 3.46-9.78). 
Eighteen flares (33%) were observed (51.5 flares per 100-patient year); the mean 
ECLAM score for the flaring patients was 2.94 (95%CI 1.97-3.91); the sites showing 
active disease and the flare management are shown in Table S4.  
 
Of the 80 patients receiving RMT, post-treatment follow-up was available in 57 (71%); 
the median follow-up after the last RTX was 13 months (IQR 4-22). Thirty (53%) flares 
were observed (38 flares per 100-patient year); the mean ECLAM score for flaring 
patients was 3.09 (95% CI 2.6-3.58); the sites showing active disease and flare 
management are shown in Table S4.  
 
The rate of flares involving major organs during RMT was 38%, this increased to 67% 
when RMT was withdrawn (p=0.01); in particular, the flare rate per 100 patient-years 
involving neurological, pulmonary and haematological systems after RMT increased 
compared to the one observed during RMT while the renal ones remained stable (figure 
2). Of note the number of flares adjusted per number of patients at risk remained 
roughly stable during the follow-up (Table S5). 
The median relapse-free survival after the last RTX infusion was 16 months in the 
cohort treated with a single-RTX course (IQR 1.2-9) and 17 months in the RMT cohort 
(IQR 4-22) (p=0.72); a trend towards a longer relapse-free survival was noted when 
considering only non-musculoskeletal flares although the difference was non significant 
(p=0.10) (figure 3). 
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Sustained responders 
Among the 80 patients of the RMT cohort, 28 (35%) did not experience any flare during 
the maintenance period (“Sustained responders”). When comparing the group of the 
“Sustained responders” to those with at least one flare, the presence of active articular 
disease at the time of the first RTX administration was at multivariate analysis 
associated with the risk of flare [OR 3.55 (95%CI 1.34-9.37) p=0.010] (Table 2) even 
after adjusting the analyses for the disease severity considered as a potential a priori 
confounder [OR 3.38 (95%CI 1.25-9.11) p=0.016]. 
 
Post-RMT follow-up was available for 21/28 of the Sustained responders (75%); the 
median follow-up was 17.5 months (IQR 5.3-23.8). 10/21 patients (48%) flared (27 
flares per 100-patient year); the mean ECLAM score for flaring patients was 2.45 
(95%CI 1.64–3.27); sites showing active disease at the time of the flare were joints in 5 
(50%), haematological in 4 (40%), renal and CNS in 2 (20%) and skin in 1 (10%). Flares 
were managed by increasing the prednisolone dose in 4 (40%), starting a new 
immunosuppressive drug in 4 (40%), increasing the dose of an on-going 
immunosuppressive drug in 1 (10%) and in three patients (30%) no treatment changes 
were recorded.    
 
Severe Adverse events 
One hundred and nine severe adverse events (SAEs) occurred in 54 patients during the 
follow-up, with a rate of 30 SAEs per 100-patient year; in the RMT subgroup the rate 
was 24 while in the single-RTX subgroup it was 53 (Table S6); the incidence of 
malignant neoplasms was 4% in the overall population and 3% in the RMT group. The 
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cumulative number and the proportions of the different SAEs did not differ between the 
patients treated with RMT and those treated with a single-RTX course (data not shown). 
 
Sixteen episodes of LON were recorded during the 452 RTX administrations (4%) in 
9/80 patients (11%) with four patients experiencing two or more episodes; ten 
episodes were of grade II, 4 of grade III and 2 of grade IV. In two patients the first 
episode of LON happened after the first RTX administration while in seven after one of 
the following cycles; the median time from the last RTX administration and the LON 
detection has been of 8 months (IQR 5-11). Of the two patients experiencing grade IV 
LON, one died of neutropenic sepsis and one was admitted for clinical monitoring 
without experiencing any infection or requiring any specific therapy. 
 
Eleven patients died during follow-up, 2/67 (3%) in the group that did not receive RMT 
and nine (9/80, 11.3%) in the RMT group; in the latter group seven died during RMT 
and two after (respectively 19 and 35 months after the last RTX infusion).  Details 
regarding the cause of death are reported in Table S7. 
 
Damage 
At the time of the first RTX administration, the mean SLICC score was 1.69 (95%CI 1.44-
1.94) in the overall population and 1.8 (95%CI 1.46-2.14) in the RMT group. Damage 
increased during the follow-up with a mean SLICC score at the last available follow-up 
of 2.14 (95%CI 1.83-2.44). 
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The increase in SLICC per patient per year pre-RTX administration was 0.21 while 
during the RMT it was 0.23; in the “Sustained responders” subgroup the increase in the 
SLICC per patient per year was 0.17. 
 
Laboratory parameters 
During RMT C3 and C4 levels remained stable if they were normal at the time of the first 
RTX administration (figure 4); in the subgroup of patients with reduced levels the 
values increased to normal and then stabilised (figure S1). IgG levels remained stable 
during the RMT whereas a trend towards reduction for IgM was noted (figure 4). Anti-
DNA levels assessed with ELISA decreased after the first RTX to fall within the normal 
range and to remain stable during the RMT (figure S2). CD19+ B-cells were 
undetectable in 76% of the patients at the time of the second RTX and tended to remain 
the same during follow-up (figure S3).  
 
DISCUSSION 
SLE remains a challenging disease being characterised by a chronic relapsing course 
despite the availability of multiple therapies. Although there have been no prospective 
trials showing superiority of RTX over placebo(4, 5), this drug is widely used. Our 
cohort of 147 patients treated with RTX is one of the largest published so far(24) and 
the overall positive response further supports the role of this drug in SLE management. 
 
Patients with low C4, with a lower number of previous immunosuppressive drugs and 
with severe disease were more likely to respond favourably: this would suggest that the 
ideal candidates for RTX may be those with more active disease and without a clear 
refractory course. This is consistent with results from other studies(10, 11). 
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Despite the challenges deriving from the management of active SLE, the maintenance 
phase plays a critical role in the long-term outcome, influencing damage accrual(7). In 
RTX treated patients time to relapse is highly variable(15, 16) and a RTX based maintenance 
treatment at fixed intervals may be attractive. 
 
Our study shows for the first time that RMT may be an option in SLE. According to our 
data, disease activity remains stable over time while allowing reduction of 
immunosuppressive drug; overall corticosteroids dose reduced after the first RTX cycle 
and the proportion of patients able to withdraw immunesoppressors at the end of the 
RMT was 41%. However, disease reactivation was common; flares were generally not 
severe, being mainly musculoskeletal and requiring only minor therapeutic changes. 
Importantly during RMT severe flares were rare while these increased when RMT was 
suspended: in particular neurological, pulmonary and haematological reactivation 
doubled. 
 
Interestingly, despite improved disease control with RMT and reduction in 
corticosteroid and immunosuppressive drug dosing, damage accumulated at the same 
rate as before the RMT phase. Damage in SLE is more likely to increase in patients 
having already experienced it as well as in the ones with renal involvement(25); 
moreover corticosteroids may cause late onset damage(26). Of interest, in an every-day 
clinical life setting study of 188 patients treated with belimumab, damage accrual rate 
decreased during the therapy although in the context of a less severe disease and lower 
damage at the beginning of the therapy (mean SLICC score of 0.85 +/- 1.11 compared to 
1.8 +/- 0.34 of this RMT cohort)(27). The RMT cohort consisted of patients with severe 
disease in 50% and active renal disease in 20%, with a long disease course and a 
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significant damage burden already recorded at time of the first RTX; in this context 
further damage progression may not be surprising. It will be of interest to observe in 
other cohorts with lower damage if this may be confirmed as well as exploring 
belimumab role on damage prevention even in groups with a high SLICC score. 
 
Among all patients treated with RMT, 35% were classified as “Sustained responders” as 
they did not experience any disease reactivation during the maintenance course; this 
group was characterised by lower damage accumulation compared to the rest of the 
population and less frequent articular involvement at the time of the first RTX 
administration. However, apart disease severity, no other confounders has been 
considered in the univariate and multivariate analyses and this result should therefore 
be interpreted with caution. No other factors associated to the risk of flares during RMT 
have been identified and future studies will need to focus on this particular aspect. 
 
After RMT the relapse free survival remains the same compared to that for patients 
treated with a single-RTX course even when excluding musculoskeletal flares. If 
confirmed, this result would not be consistent with the experience of RMT in AAV(28). 
This data, although of interest, should be interpret with caution being the result of a 
comparison performed between two heterogeneous and non-matched groups; 
moreover, the RMT cohort was probably represented by patients with a more severe 
disease profile as suggested by the higher proportion of TF 6 months after the first RTX 
administration compared to the Single-RTX group. Importantly, relapse rate after RMT, 
may have been influenced by the natural course of the disease since no adjustment for 
this has been performed in our analyses; the role of RMT suspension on post RMT flares 
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has therefore to be confirmed. However reassuringly a clear trend for increase of the 
relapse rate during the follow-up has not been identified. 
 
The mortality observed in our cohort is within the high range of what described in 
literature especially in the RMT group (11.3%): we feel that this may be consequence of 
the high risk profile of this population. Of note, patients with severe comorbidities are 
usually excluded from RCTs and the mortality rate in studies including patients with 
similar profile of severity is around 8%(29). Reassuringly, cancer risk was similar to the 
one described in the literature. 
 
Importantly, LON incidence in the RMT group (4% of the RTX administrations in 11% of 
the patients) was higher than what described in other cohorts of RTX treated patients 
with heterogeneous immunological diseases (2%)(30) but lower than what described in 
other SLE cohorts (29.9%)(31). Only two episodes observed in the RMT group 
happened after the first RTX administration while the remaining 14 were recorded after 
subsequent administrations suggesting a possible role for repeat RTX in increasing LON 
risk; four patients experienced two or more episodes. Of note, one patient of the RMT 
cohort died of neutropenic sepsis. 
 
Our study is a multicentre – multidisciplinary survey involving a large cohort collected 
from tertiary care centres with experience in managing SLE. However, when 
interpreting these results, several observations have to be made. As a retrospective 
study, some heterogeneity across different centres must be taken into account as shown 
by the variability of the treatment schemes during RMT; moreover only 89% of the 
population followed a pre-planned RTX scheme of administration while 9% entered a 
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fixed interval scheme only within 8 months from the first RTX administration and 2% 
were treated irregularly according to changes in symptoms and serology; importantly 
11% of the patients supposed to be treated regularly missed at least one administration 
during the first 24 months of treatment. All these factors, in the context of a highly 
variable timing of relapse in RTX-treated SLE patients(15, 16), may have contributed to 
the high flare rate observed in our population. Whether this RMT protocol should be 
considered as a genuine relapse prevention approach rather than a repeat induction is 
unclear and this will need to be tested in a prospective fashion. Importantly, post-
treatment follow-up was relatively short and conclusions regarding this phase of the 
study should be interpreted with caution.  
 
Of note, 51/147 (35%) patients had articular and mucocuteneous manifestations as 
prominent feature of active SLE at the moment of the first RTX; all of these patients had 
received corticosteroids and hydroxycloroquine in their past as well as at least one drug 
among MMF, MTX and AZA with 39% having received two of them. Despite the 
proportion of patients treated with MTX in our cohort was higher compared to the 
BLISS trials (7-21.2%)(32, 33), still only 50% and 41% of the potentially eligible 
patients with respectively articular and mucocutanous disease received this drug in 
their history. This may reflect a more limited experience with this drug of the 
nephrologists involved in the study as well as safety concerns related to MTX use(34). 
Moreover, according to the timing of reimbursement approval from the Italian and UK 
Health Systems, 5% of our cohort would have been eligible for belimumab and was 
however treated with RTX; this may have been consequence of a greater experience 
with RTX of the investigators involved in this study. However, reassuringly, no center-
effect was noted for RTX, MTX and belimumab prescription. The high rate of patients 
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with musculoskeletal and skin involvement may be the reason of the relatively high 
proportion of patients with mild disease treated with RTX in our population (26%); this 
group, according to the guidelines of the British Society of Rheumatology(8), should not 
be treated with RTX. However it is to be noted that for patients with less severe disease, 
RTX was employed in the context of reduced therapeutic options having this population 
previously failed a mean of around 3 immunosuppressive drugs. Another limitation is 
that for 18% of the patients, a single-RTX cycle had been employed before the referral 
to the centers of this study: at the moment of the inclusion in our survey however all 
these patients were B-cell repopulated. Our population might therefore not necessarily 
reflect other centers or nowadays clinical practice especially with belimumab being 
more easily available. 
 
The response criteria employed are original and not validated; however response 
definitions in retrospective RTX treated SLE cohorts have been historically 
heterogeneous and reassuringly in our population response rates are in keeping with 
the literature(1). Together with the change of a semi-objective score such as ECLAM, PA 
has been employed due to the central role of the physician judgment for the assessment 
of a complex disease such as SLE while the immunesuppressant dose reduction has 
been included since in this cohort RTX has been frequently employed with the aim of 
sparing other drugs. 
 
In conclusion, we confirm in a large multicentre cohort that RTX may be an option in 
patients with SLE. Its use as maintenance treatment allows corticosteroid and 
immunosuppressive drug sparing while stabilising the overall disease activity; however 
is to be noted that musculoskeletal flares were common. Patients without articular 
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involvement at the time of the first RTX were less likely to experience relapses during 
RMT. At the time of drug withdrawal, relapse free survival remains apparently 
comparable to the one of patients treated with a single-RTX course. A RMT regimen 
might be considered for patients with severe disease-related complications, for whom 
waiting for the relapse in order to treat on demand may be risky, and when first-line 
immunosuppressive options are exhausted. 
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TABLES AND FIGURES 
 
Table 1. Main characteristics of the 147 SLE patients treated with RTX.. 
 RMT (n=80) Single-RTX 
(n=67) 
Overall cohort 
(n=147) 
Age (years) 45 (42-48)  42 (39-46) 44 (41-46) 
Gender - Female 71 (90%) 63 (94%) 134 (91%) 
Ethnicity - Caucasian 74 (93%) 62 (93%) 136 (93%) 
Prior disease duration (months) 154 (100-208)  114 (87-141) 
 
133 (104-161) 
RTX given at the time of diagnoses  3 (4%) 4 (6%) 7 (5%) 
Organ manifestations at first RTX 
administration 
   
Musculoskeletal 52 (65%) 35 (53%) 87 (60%) 
Skin 49 (61%) 31 (46%) 80 (54%) 
Haematological 26 (33%) 37 (55%) 63 (43%) 
Pulmonary 18 (23%) 6 (9%) 24 (16%) 
Renal 15 (19%) 37 (55%) 52 (36%) 
Neurological 14 (18%) 8 (12%) 22 (15%) 
Previous therapies    
Mycophenolate mofetil 67 (84%) 42 (63%) 109 (74%) 
Hydroxychloroquine 61 (76%) 38 (57%) 99 (67%) 
Azathioprine 41 (51%) 26 (39%) 67 (46%) 
Methotrexate 26 (33%) 13 (19%) 39 (27%) 
Cyclophosphamide 24 (30%) 21 (31%) 45 (31%) 
Rituximab  14 (18%) 12 (18%) 26 (18%) 
Calcineurin inhibitor 11 (14%) 24 (36%) 35 (24%) 
Anti-TNF therapy 6 (8%) 3 (4%) 9 (6%) 
Plasma exchange 4 (5%) 2 (3%) 6 (4%) 
IV immunoglobulins 4 (5%) 6 (9%) 10 (7%) 
Other  10 (13%) 9 (13%) 19 (13%) 
Previous immunosuppressive 
therapies per patient £ 
4.3 (4-4.7) 3.9 (3.5-4.4) 4.1 (3.9-4.4) 
Severity of Disease    
Mild 20 (25%) 4 (6%) 24 (16%) 
Moderate 6 (7%) 17 (25%) 23 (16%) 
Severe 40 (50%) 34 (51%) 74 (50%) 
Drug Sparing 14 (18%) 12 (18%) 26 (18%) 
Laboratory Data     
Anti-DNA level (IU/mL) 67.2 (31.9-104.5) 75.4 (39-111.5)  71 (46-96)  
C3 (g/L) 1.1 (1.02-1.21)  0.85 (0.75-94)  1 (0.92-1.07)   
C4 (g/L) 0.2 (0.18-0.24)  0.15 (0.12-0.18)  0.18 (0.16-0.2)  
Response to RTX at 6 months    
Complete Response 32 (40%) 35 (52%) 67 (45%) 
Partial Response 21 (26%) 20 (30%) 41 (28%) 
Treatment Failure 27 (34%) 12 (18%) 39 (27%) 
RMT: Rituximab Maintenance Treatment 
Results are expressed as n/N (%) for categorical variables and mean (95%CI) for 
continuous variables. 
£ Includes also hydroxychloroquine 
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Table 2. Clinical characteristics and their association with the risk of experiencing 
at least one flare during the RMT at univariate and multivariate analyses 
 
° Odds ratio expressed for 0.1 increase  
$ Odds ratio expressed for unit increase of the independent variable 
 
 
 Univariate Multivariate 
Variable Odds ratio p Odds ratio p 
Gender 
 
Female (reference) 
 
Male 
 
 
1 
 
4.8 (0.57-40.5) 
0.150 - - 
Number of immunosuppressive drugs 
before RTX 
 
0-2 (reference) 
 
3-4 
 
>4 
 
 
1 
 
1.51 (0.51-4.46) 
 
0.93 (0.22-4) 
0.650 - -
Physician Assessment at RTX 
 
0 
 
1 
 
2 
 
 
1 
 
2.81 (0.39-20.4) 
 
3.08 (0.47-20.23) 
0.501 - - 
Clinical manifestations at RTX     
Systemic 2.00 (0.77-5.16) 0.150 - -
Articular  3.55 (1.34-9.37) 0.011 3.55 (1.34-9.37) 0.011 
Skin  2.67(1.04-6.87) 0.042 - - 
Muscle  0.51 (0.07-3.83) 0.512 - -
Pulmonary 1.65 (0.53-5.18) 0.390 - -
CNS 2.18 (0.55-8.58) 0.264 - - 
Renal 0.56 (0.18-1.754) 0.316 - - 
Hematologic  0.64 (0.24-1.70) 0.373 - -
ECLAM score at RTX $ 1.02 (0.80-1.29) 0.887 - - 
Laboratory Values at RTX     
Anti-DNA titre $ 1.001 (0.997-1.006) 0.615 - - 
C3° 1.02 (0.89-1.17) 0.786 - - 
C4° 1.21 (0.72-2.05) 0.474 - -
Other immunosuppressors with RTX 1 (0.47-2.09) 0.993 - - 
Dose of prednisolone at the time of RTX 0.95 (0.91-1.01) 0.079 - - 
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Figure 1.  Changes of the ECLAM score, prednisolone and immunosuppressive 
treatment in the 80 SLE patients who received RTX Maintenance Treatment 
(RMT) for relapse prevention. 
Panel A. Data are shown as mean with whiskers representing the 95% confidence 
interval. The grey area includes the part of the follow-up after the first RTX 
administration. The * indicates a reduction of ECLAM score statistically significant 
compared to baseline 
Panel B. Bars show the proportion of patients either receiving (light grey) or not 
receiving (dark grey) other immunosuppressive drugs at the moment of the first RTX 
administration and during the RMT; the line represents the changes in the mean 
(95%CI) prednisolone (PDN) dose. The star highlights a significant difference compared 
to baseline (p<0.05). 
 
 
Figure 2.  Major organ involvement at the time of flare during and after RTX 
Maintenance Treatment (RMT) 
 
 
Figure 3.  Relapse free survival of two cohorts of patients with SLE after the last 
RTX administration. 
The red curve is showing the relapse free survival in a group of patients treated with a 
single-RTX course, the green curve the relapse free survival in cohort treated with RTX 
Maintenance Treatment (RMT) after the last RTX course. 
Panel A refers to the overall population, Panel B included as event only the non-
musculoskeletal flares. 
 
 
Figure 4.  Complement and immunoglobulin levels during follow-up in a cohort of 
80 SLE patients receiving RTX Maintenance Treatment (RMT) with the aim of 
relapse prevention. 
Data are provided as mean, error bars represent 95%CI. The grey area of the figure 
represents values within the normal range. The star highlights a significant difference 
compared to baseline (p<0.05). 
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